Tags : New Biotech Lab

Biosimilars

Xbrane to Initiate New Biosimilar Development Program Annually

Shots: Xbrane to initiate a new biosimilar development program annually and planning to generate positive operating cash flow monthly on the back of expected Xlucane net-income by late 2023/early 2024 Xlucane (biosimilar, ranibizumab) referencing Lucentis is currently in the P-III trial with expected results in mid-2021, regulatory submissions are underway in the EU in Q3 […]Read More